A Prospective Multicenter Open-Label Study of the Effectiveness of Epoetin Beta for Patients with Low/Intermediate-1-Risk Myelodysplastic Syndrome (MDS): A Preliminary Result

被引：2
|
作者：
Chuncharunee, Suporn [1 ]
Kanitsap, Nonglak [2 ]
Suwanban, Tawatchai [3 ]
Khuhapinant, Archrob [4 ]
Uaprasert, Noppacharn [5 ]
Chansung, Kanchana [6 ]
Rattarittamrong, Ekarat [7 ]
Wongkhantee, Somchai [8 ]
Siritanaratanakul, Noppadol [4 ]
Norasetthada, Lalita [7 ]
Nakorn, Thanyaphong Na [5 ]
Charnwiboonsri, Chadchai [9 ]
机构：
[1] Mahidol Univ, Ramathibodi Hosp, Dept Internal Med, Bangkok, Thailand
[2] Thammasat Univ, Dept Internal Med, Pathum Thani, Thailand
[3] Rajavithi Hosp, Dept Internal Med, Bangkok, Thailand
[4] Mahidol Univ, Siriraj Hosp, Dept Med, Bangkok, Thailand
[5] Chulalongkorn Univ, Dept Med, Bangkok, Thailand
[6] Khon Kaen Univ, Dept Internal Med, Khon Kaen, Thailand
[7] Chiang Mai Univ, Dept Internal Med, Chiang Mai, Thailand
[8] Khonkaen Reg Hosp, Dept Internal Med, Khon Kaen, Thailand
[9] Roche Thailand Ltd, Med Dept, Bangkok, Thailand
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.5543.5543
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5543
引用
收藏
页数：4
相关论文
共 50 条
  • [41] Effectiveness and tolerability of the buprenorphine transdermal system in patients with moderate to severe chronic pain:: A multicenter, open-label, uncontrolled, prospective, observational clinical study
    Muriel, C
    Failde, I
    Micó, JA
    Neira, M
    Sánchez-Magro, I
    CLINICAL THERAPEUTICS, 2005, 27 (04) : 451 - 462
  • [42] Anti-PD-1 antibody (sintilimab) plus decitabine as first-line treatment for patients with higher-risk myelodysplastic syndrome (MDS): Preliminary results from a single-arm, open-label, phase II study.
    Wang, Jing
    Li, Siqi
    Jiang, Hao
    Chang, Ying-Jun
    Zhao, Xiao-Su
    Jia, Jin-Song
    Zhu, Xiao-Lu
    Gong, Li-Zhong
    Liu, Xiao-Hong
    Yu, Wen-Jing
    Huang, Xiao-Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [43] CLINICAL FACTORS PREDISPOSING TO ACHIEVEMENT OF RBC TRANSFUSION INDEPENDENCEIN LENALIDOMIDE-TREATED PATIENTS WITH LOW/INTERMEDIATE-1-RISK MYELODYSPLASTIC SYNDROMES) WITHOUT DEL(5q) IN MDS-005 STUDY
    Santini, V.
    Li, J. Shiansong
    Swern, A. S.
    Almeida, A.
    Giagounidis, A.
    Fu, T.
    Sanna, A.
    Hoenekopp, A.
    Beach, C. L.
    Skikne, B.
    Fenaux, P.
    HAEMATOLOGICA, 2015, 100 : 3 - 4
  • [44] Results of a Phase 2, Open-Label Study of Idarubicin (I), Cytarabine (A) and Nivolumab (Nivo) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)
    Assi, Rita
    Kantarjian, Hagop M.
    Daver, Naval G.
    Garcia-Manero, Guillermo
    Benton, Christopher B.
    Thompson, Philip A.
    Borthakur, Gautam
    Kadia, Tapan M.
    Alvarado, Yesid
    Jabbour, Elias J.
    Konopleva, Marina Y.
    Takahashi, Koichi
    Kornblau, Steven M.
    DiNardo, Courtney D.
    Estrov, Zeev E.
    Flores, Wilmer
    Basu, Sreyashi
    Allison, James P.
    Sharma, Padmanee
    Pierce, Sherry A.
    Pike, Allison
    Cortes, Jorge E.
    Ravandi, Farhad
    BLOOD, 2018, 132
  • [45] MDS-005 STUDY: EFFECT OF BASELINE ENDOGENOUS ERYTHROPOIETIN ON RBC TRANSFUSION INDEPENDENCE IN LENALIDOMIDE-TREATED PATIENTS WITH LOW OR INTERMEDIATE-1-RISK MYELODYSPLASTIC SYNDROMES WITHOUT DEL(5Q)
    Santini, V.
    Li, J. S.
    Swern, A. S.
    Almeida, A.
    Giagounidis, A.
    Fu, T.
    Hoenekopp, A.
    Beach, C.
    Skikne, B.
    Fenaux, P.
    HAEMATOLOGICA, 2015, 100 : 69 - 69
  • [46] Randomized Phase II Study Evaluating the Efficacy and Safety of Romiplostim Treatment of Patients with Low or Intermediate Risk Myelodysplastic Syndrome (MDS) Receiving Lenalidomide
    Lyons, Roger M.
    Larson, Richard A.
    Kosmo, Michael A.
    Gandhi, Sunil
    Liu, Delong
    Chernoff, Marc
    Dreisbach, Luke
    Matei, Carmen
    Hu, Kuolong
    Franklin, Janet L.
    Berger, Dietmar
    BLOOD, 2009, 114 (22) : 703 - 704
  • [47] Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS)
    C. Ola Landgren
    Ajai Chari
    Yael C. Cohen
    Andrew Spencer
    Peter Voorhees
    Jane A. Estell
    Irwindeep Sandhu
    Matthew W. Jenner
    Catherine Williams
    Michele Cavo
    Niels W. C. J. van de Donk
    Meral Beksac
    Philippe Moreau
    Hartmut Goldschmidt
    Steven Kuppens
    Rajesh Bandekar
    Pamela L. Clemens
    Tobias Neff
    Christoph Heuck
    Ming Qi
    Craig C. Hofmeister
    Leukemia, 2020, 34 : 1840 - 1852
  • [48] Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS)
    Landgren, C. Ola
    Chari, Ajai
    Cohen, Yael C.
    Spencer, Andrew
    Voorhees, Peter
    Estell, Jane A.
    Sandhu, Irwindeep
    Jenner, Matthew W.
    Williams, Catherine
    Cavo, Michele
    van de Donk, Niels W. C. J.
    Beksac, Meral
    Moreau, Philippe
    Goldschmidt, Hartmut
    Kuppens, Steven
    Bandekar, Rajesh
    Clemens, Pamela L.
    Neff, Tobias
    Heuck, Christoph
    Qi, Ming
    Hofmeister, Craig C.
    LEUKEMIA, 2020, 34 (07) : 1840 - 1852
  • [49] A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial with Aripiprazole (BETA)
    Tandon, Rajiv
    Marcus, Ronald N.
    Stock, Elyse G.
    Riera, Linda C.
    Kostic, Dusan
    Pans, Miranda
    McQuade, Robert D.
    Nyilas, Margaretta
    Iwamoto, Taro
    Crandall, David T.
    SCHIZOPHRENIA RESEARCH, 2006, 84 (01) : 77 - 89
  • [50] A multicenter, open-label, prospective, randomized, dose-ranging pharmacokinetic study of the anti-TNF-α antibody afelimomab in patients with sepsis syndrome
    James Gallagher
    Charles Fisher
    Bruce Sherman
    Mark Munger
    Bruce Meyers
    Travis Ellison
    Steven Fischkoff
    William T. Barchuk
    Leah Teoh
    Raja Velagapudi
    Intensive Care Medicine, 2001, 27 : 1169 - 1178
12345